ArticleBMC gastroenterology2025
The ratio of GGT to PLT indices is a predictive factor for the progression of liver fibrosis in NA-treated chronic hepatitis B patients with advanced fibrosis plus PEG-IFN α-2a therapy: a case-control study.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
BACKGROUND/
objectiveCombination therapy with pegylated interferon α-2a (PEG-IFN α-2a) and nucleoside analogue (NA) has been shown to improve liver histology in patients with chronic hepatitis B (CHB) and hepatic fibrosis. PEG-IFN α-2a effectiveness was assessed in NA-treated CHB patients with advanced fibrosis/compensated cirrhosis.
methodsThis retrospective multicenter study included NA-treated CHB patients with advanced fibrosis/compensated cirrhosis. Patients received 48-week PEG-IFN α-2a plus 24-week follow-up. The primary endpoint was liver fibrosis status 24 weeks post-treatment.
resultsA total of 102 patients were enrolled in the study, including 35 and 67 baseline HBeAg-positive and HBeAg-negative CHB patients, respectively. At the end of PEG-IFN α-2a treatment, a total of 18 (17.6%) patients achieved HBsAg loss, and 23 (65.7%) achieved HBeAg loss. Sixty-nine patients completed the comparison of liver fibrosis and cirrhosis before and after treatment, of whom 16 (23.2%) experienced progression of liver fibrosis or cirrhosis, 32 (46.4%) experienced liver fibrosis reversal, and 21 (30.4%) remained stable. Penalized logistic regression analysis demonstrated that GPR (Intercept = -1.200; Coefficients = 0.102) and GGT levels (Intercept = -1.198; Coefficients = 0.048) at 24 weeks of PEG-IFN α-2a treatment were independent predictors of fibrosis progression. Among these, GPR at 24 weeks exhibited the highest predictive value (Corrected AUC = 0.805).
conclusionApproximately one-fifth of the NA-treated CHB patients with advanced liver fibrosis and compensated cirrhosis experienced progression of liver fibrosis after PEG-IFN α-2a treatment. The GPR at 24 weeks of treatment was an independent predictive factor for the progression of liver fibrosis in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.